Gene Expression Of TMEM178 Decreases With The Progression Of Asthma Severity Naiya B. Patel, MD, Lorena Ostilla, MD, Lyda Cuervo-Pardo, MD, Sergejs Berdnikovs, PhD, and Sergio E. Chiarella, MD; Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. RATIONALE: The transmembrane protein 178 (Tmem178) is a novel negative regulator of the nuclear factor of activated T-cells, cytoplasmic 1 (NFAT1c); a recognized player in asthma pathogenesis. Our group has previously shown that changes in TMEM178 gene expression are associated with lower airway obstruction in asthmatics having an acute respiratory illness-induced exacerbation. We sought to compare the relative gene expression of TMEM178 in the airway epithelium of severe asthmatics to that in the airway epithelium of non-severe asthmatics and healthy controls.
METHODS:
We performed a secondary analysis of two high-quality publicly available microarray datasets (National Center for Biotechnology Information's Gene Expression Omnibus database; accession numbers GSE43696 and GSE63142), which contained epithelial brushings obtained by bronchoscopy from asthmatics and healthy donors. For differential gene expression comparisons, moderated Benjamini-Hochberg t-tests (with false discovery rate adjustments) and Dunn's multiple comparison tests were used. RESULTS: In the first microarray study (GSE43696), severe asthmatics had significantly lower levels of TMEM178 gene expression when compared to moderate asthmatics (p-value <0.05) and healthy controls (p-value <0.0001). Similarly, in the second microarray study (GSE63142), severe asthmatics had significantly lower levels of TMEM178 gene expression when compared to non-severe asthmatics (pvalue <0.001) and healthy controls (p-value <0.0001). Overall, TMEM178 gene expression negatively correlates with asthma severity. CONCLUSIONS: In two independent microarray studies, the relative gene expression of TMEM178 decreased with the progression of asthma severity. We speculate that Tmem178 may play an important role in the regulation of NFAT-induced inflammation in severe asthmatics.
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Multi-Omic Profiling Of Asthma Using HighThroughput Sequencing
Gopal Krishna Dhondalay, PhD
Stanford University, Stanford, CA. RATIONALE: Asthma is a chronic allergic inflammatory disease affecting over 300 million people worldwide and increasing with alarming rate in developing countries. The etiologies of asthma and disease progression depend on many factors, including genetic and epigenetic inheritance. As the genetic profile of any individual is regulated by their epigenetic makeup, the investigation of genetic markers and their corresponding epigenetic footprint in asthmatic individuals is of great importance to the understanding of the disease biology. METHODS: This study comprises 16 pairs of twins, concordant and discordant for asthma, among which 13 were asthmatic and 19 were nonasthmatic individuals. In all of the 16 twin pairs, the transcriptomic RNAseq was performed using TopHat2 aligner, Cufflinks assembler and DESeq2 for differential expression. Methyl-seq was done on a subset of 8 twin pairs using whole-genome bisulfite sequencing, Bismark aligner and methyl-extractor. RESULTS: Across all asthmatic and non-asthmatic samples, 764 genes were differentially expressed and 22873 CpG sites were found to be differentially methylated. Among the most significant genes (Q < 0.1), RNF114, CD3G, ZNF418 and SLC41A3 were found to be biologically relevant. Significant CpG methylations were found on the SC5D, DHX58 and SLC12A7 genes (p < 0.05). There were 470 differentially expressed genes which also had one or more CpG methylation changes, representing a shared transcriptomic and epigenetic signature. CONCLUSIONS: Our twin cohort elucidated changes in the transcriptome and epigenome among asthmatics and non-asthmatics. Further integrative multi-omic investigations are needed to elucidate the regulatory effects of CpG methylations and their network inference. 
